Results 201 to 210 of about 2,920,676 (267)

Spatial and single‐nuclei transcriptomics reveals idiosyncratic and generic patterns in papillary and anaplastic thyroid cancers

Molecular Oncology, EarlyView.
Matched spatial transcriptomics and single‐nuclei RNA‐seq were generated for anaplastic and BRAFV600E papillary thyroid cancers revealing generic and tumor‐specific states occurring in cancer cells and in the tumor microenvironment. In this context, cancer dedifferentiation mirrored organoid maturation through ordered thyroid marker gain/loss ...
Adrien Tourneur, Joel Rodrigues Vitória, Manuel Saiselet, Ligia Craciun, Denis Larsimont, Anne Lefort, Frédérick Libert, Carine Maenhaut, Sabine Costagliola, Maxime Tarabichi, Mirian Romitti, Vincent Detours   +11 more
wiley   +1 more source

Unveiling the therapeutic potential of gut microbiota metabolites for the treatment of renal fibrosis based on network pharmacology study. [PDF]

Bioresour Bioprocess
Yao W, Huo J, Liu K, Tao P.
europepmc   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Therapeutic pathways for ischemic stroke patients in France: a national hospitalization database study. [PDF]

Front Neurol
Derex L, Tardu J, Caumette D, Chollet J, Cabout E, Cancalon C, Bugnard F, Lollichon A, Smadja D.   +8 more
europepmc   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Preconditioning with sufentanil confers protective effects in transplantation by attenuating hepatic ischemia-reperfusion injury. [PDF]

World J Transplant
Mouratidou C, Pavlidis ET, Katsanos G, Kofinas A, Marneri AG, Stavrati KE, Tsoulfas G, Pavlidis TE.   +7 more
europepmc   +1 more source

The three causal pathways of ENSO teleconnections to High Mountain Asia winter precipitation. [PDF]

Clim Dyn
Borah PJ, Mamalakis A, Guilloteau C, Tejedor A, Foufoula-Georgiou E.   +4 more
europepmc   +1 more source

Platonic Pathways

Les platonismes de l'Antiquité Tardive, 2018
openaire   +2 more sources

Cancer stem cells and their molecular signaling mechanisms in tongue squamous cell carcinoma (Review). [PDF]

Oncol Lett
Guo X, Zhou X, Ran W, Zhu Q, Chen W, Ma C.   +5 more
europepmc   +1 more source